[18F]-AraG PET Imaging in LA HNSCC
Starting soon · Early Phase 1
Conditions studied: Head and Neck Squamous Cell Carcinoma (HNSCC), Locally Advanced Head and Neck Squamous Cell Carcinoma
In brief
This study will use \[18F\]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for treatment.
Key facts
- Study ID
- NCT07168785
- Run by
- Indiana University
- People needed
- 5
- Starts
- 2026-09-01
- Expected to finish
- 2027-10-01
- Last updated by the study team
- 2026-07-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients ≥18 years of age.
- Ability to provide written informed consent and HIPAA authorization.
- LA-HNSCC in the larynx, hypopharynx, or human papillomavirus (HPV) negative oropharynx and is planning to receive definitive CRT as the SOC treatment, which includes a total of 70 Gy of radiation dose in 35 fractions, delivered over 5 days a week for 7 weeks, as well as planned weekly cycles of cisplatin (CDDP).
- Tumor stage III and IV (AJCC 8th edition).
- Unresectable cases.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Willing and able to maintain the imaging protocol.
- Patients planning to receive pre-CRT and post-CRT FDG PET/CT scans as part of the standard clinical practice.
You may not qualify if…
- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the PET/CT scan.
- Pregnant or breastfeeding.
- Patients that will receive definitive induction chemotherapy or surgery.
- Patients who are unable to complete the radiation therapy.
Where it is running
- Indiana University — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.